|
Tumor and serum basic fibroblast growth factor (bFGF) in relation to clinical, pathological and biological characteristics in breast cancer patients |
||||||
| Tumor bFGF |
Serum bFGF |
|||||
|
|
||||||
| Number of cases |
% positive cells [median (range)] |
P |
Number of cases |
Serum level (pg/ml) [median (range)] |
P |
|
|
|
||||||
| Age |
||||||
| 51–70 years |
41 |
45 (0–90) |
0.25 |
46 |
2.2 (0.3–15.1) |
0.40 |
| > 70 years |
22 |
65 (5–100) |
27 |
3.0 (0.4–26.6) |
||
| Histotype |
||||||
| Ductal |
54 |
55 (0–100) |
0.68 |
60 |
2.2 (0.3–26.6) |
0.90 |
| Others |
9 |
60 (0–85) |
13 |
2.3 (0.4–5.2) |
||
| Tumor size |
||||||
| ≤ 2 cm |
43 |
55 (5–100) |
0.53 |
51 |
2.3 (0.3–26.6) |
0.37 |
| > 2 cm |
20 |
63 (5–100) |
21 |
1.9 (0.4–11.1) |
||
| Node status |
||||||
| Node-negative |
30 |
63 (0–100) |
0.69 |
35 |
2.5 (0.3–15.1) |
0.43 |
| Node-positive |
27 |
65 (0–100) |
28 |
2.0 (0.5–26.6) |
||
| Grade |
||||||
| 1–2 |
38 |
62.5 (0–100) |
0.99 |
42 |
2.3 (0.3–15.1) |
0.57 |
| 3 |
12 |
60 (5–100) |
13 |
3.1 (1.5–26.6) |
||
| Steroid status |
||||||
| ER-positive |
43 |
45 (0–100) |
0.43 |
49 |
2.2 (0.3–15.1) |
0.32 |
| ER-negative |
10 |
65 (5–95) |
11 |
3.5 (1.8–11.1) |
||
| PgR-positive |
32 |
38 (0–100) |
0.12 |
35 |
2.0 (0.4–8.6) |
0.19 |
| PgR-negative |
21 |
70 (5–95) |
25 |
2.5 (0.3–15.1) |
||
|
ER, estrogen receptor; PgR, progesterone receptor. | ||||||
Granato et al. Breast Cancer Res 2004 6:R38 doi:10.1186/bcr745 |
||||||